Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: October-29-14
Credit Expiration Date: October-29-15

Faculty

Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Clinical Professor of Dermatology
University of Texas, Southwestern Medical School
Dallas, TX

Craig Leonardi, MD
Clinical Professor, Dermatology
St. Louis University
Central Dermatology
St. Louis, MO

Credit Hours

0.75 AMA PRA Category 1 Credit

Medium

i-Newsletter

Program Description

Psoriasis is a multisystem, immune-mediated, inflammatory disease, manifesting as chronic inflammation of the skin as well as joints in a subgroup of patients. Approximately 2% to 3% of the US population (an estimated 7.5 million Americans) has psoriasis. Plaque psoriasis, the most common form, affects 80% to 90% of individuals with psoriasis. Moderate to severe plaque psoriasis is often disfiguring, sensitive, and painful. Despite advances in treatment, moderate to severe plaque psoriasis continues to have a substantial negative impact on patients’ quality of life, significantly affecting their overall emotional well-being, social and personal interactions, as well as enjoyment of life. Biologic therapies represent a significant advance in the treatment of moderate to severe plaque psoriasis, targeting specific abnormal immune system responses that contribute to the disease. Currently approved biologics for psoriasis target TNF-alpha and the IL-12/23 pathways. Numerous investigational biologics targeting additional pathways are in the late stages of clinical development and hold promise for further improving the treatment of moderate to severe plaque psoriasis.

Program Developer/Facilitator


.

Target Audience

This activity is intended for dermatologists and other clinicians involved in the treatment of patients with moderate to severe plaque psoriasis.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe characteristics of patients with moderate to severe plaque psoriasis who may benefit from treatment with systemic therapies.
  2. Summarize safety and efficacy data of biologic therapies currently approved for the treatment of moderate to severe plaque psoriasis.
  3. Compare the mechanisms of action of emerging investigational biologic agents for moderate to severe plaque psoriasis that selectively target specific components of the immune system.
  4. Discuss best practices for the use of biologic therapies, including combination therapy, with current systemic phototherapeutic and topical agents as well as managing treatment failures.

Disclosures

The University of Chicago Pritzker School of Medicine requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by The University of Chicago for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Alan Menter, MD discloses the following:
Advisory Board: AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genentech, Janssen Biotech, Inc., LEO Pharma, Pfizer
Consultant: AbbVie, Allergan, Amgen, Convoy Therapeutics, Inc., Eli Lilly, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, Syntrix, Wyeth, XenoPort
Investigator: AbbVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics, Inc., Eli Lilly, Genentech, Janssen Biotech, Inc., LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix, Wyeth
Speaker: AbbVie, Amgen, Janssen Biotech, Inc., LEO Pharma, Wyeth

Craig Leonardi, MD discloses the following:
Consultant: AbbVie, Amgen, Eli Lilly, Janssen, LEO Pharma, Pfizer, Sandoz, UCB
Investigator: AbbVie, Amgen, Anacor, Celgene, Coherus, Eli Lilly, Galderma, Janssen, LEO Pharma, Maruho, Merck, Novartis, Novo Nordisk, Pfizer, Stiefel, Tolmar, Warner Chilcott, Wyeth.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The staff of the University of Chicago Center for Continuing Medical Education have no financial relationships to disclose.

Gena Dolson, MCM Senior Medical Writer, has nothing to disclose

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. University of Chicago and MCM Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other health care professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Commercial Support Statements

This activity is supported by independent education grants from AbbVie, Inc., and Novartis Pharmaceuticals Corporation.

Certificate Fee

$0.00

Disclaimer

©2014, MCM Education. All rights reserved. This activity is designed to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. None of the content may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this interactive newsletter are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, The University of Chicago, AbbVie, or Novartis. Any medications or other diagnostic or treatment procedures presented by the program faculty should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS